Abbott Laboratories (ABT) Retained Earnings (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Retained Earnings data on file, last reported at -$6.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 113.23% year-over-year to -$6.3 billion; the trailing twelve-month figure through Mar 2026 stood at -$6.3 billion (down 113.23% YoY), and the FY2025 full-year result was -$6.0 billion, down 112.7% from the prior year.
• Retained Earnings slipped to -$6.3 billion in Q1 2026, from -$6.0 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $49.1 billion in Q3 2025 to a low of -$9.4 billion in Q3 2022.
• A 5-year average of $18.5 billion and a median of $34.5 billion in 2022 frame the typical range for Retained Earnings.
• Peak annual rise in Retained Earnings reached 702.9% in 2024, while the deepest fall reached 122.77% in 2024.
• Tracing ABT's Retained Earnings over 5 years: stood at -$8.1 billion in 2022, then rose by 2.63% to -$7.8 billion in 2023, then jumped by 702.9% to $47.3 billion in 2024, then plunged by 112.7% to -$6.0 billion in 2025, then slipped by 5.18% to -$6.3 billion in 2026.
• Business Quant data shows ABT's Retained Earnings at -$6.3 billion in Q1 2026, -$6.0 billion in Q4 2025, and $49.1 billion in Q3 2025.